Compugen Ltd [CGEN] stock prices are up 10.94% to $2.94 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CGEN shares have gain 11.36% over the last week, with a monthly amount glided 40.00%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 6, March 2024, Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024. In a post published today on Yahoo Finance, Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present data from its differentiated immuno-oncology preclinical and clinical pipeline, in two poster presentations at the American Association for Cancer Research (AACR) annual meeting on April 5-11, 2024, in San Diego, California.
From an analyst’s perspective:
Compugen Ltd [NASDAQ: CGEN] stock has seen the most recent analyst activity on August 05, 2022, when Jefferies downgraded its rating to a Hold but kept the price target unchanged to $2 for it. On May 13, 2020, Stifel initiated with a Buy rating and assigned a price target of $19 on the stock. SVB Leerink started tracking the stock assigning a Outperform rating. ROTH Capital initiated its recommendation with a Buy and recommended $28 as its price target on April 22, 2020. SunTrust started tracking with a Buy rating for this stock on March 24, 2020, and assigned it a price target of $16. In a note dated January 16, 2020, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $10 on this stock.
The stock price of Compugen Ltd [CGEN] has been fluctuating between $0.53 and $2.99 over the past year. Compugen Ltd [NASDAQ: CGEN] shares were valued at $2.94 at the most recent close of the market.
Analyzing the CGEN fundamentals
The Compugen Ltd [NASDAQ:CGEN] reported sales of 33.46M for trailing twelve months, representing a surge of 346.12%. Gross Profit Margin for this corporation currently stands at 0.87% with Operating Profit Margin at -4.6%, Pretax Profit Margin comes in at -4.2%, and Net Profit Margin reading is -4.21%. To continue investigating profitability, this company’s Return on Assets is posted at -0.47, Equity is -0.48 and Total Capital is -0.6. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.76 points at the first support level, and at 2.59 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.07, and for the 2nd resistance point, it is at 3.21.
Compugen Ltd [CGEN] reported earnings per share of $0.11 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.22/share, meaning a difference of -$0.11 and a surprise factor of -50.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.11 per share as compared to estimates of -$0.09 per share, a difference of -$0.02 representing a surprise of -22.20%.
Ratios To Look Out For
It’s worth pointing out that Compugen Ltd [NASDAQ:CGEN]’s Current Ratio is 4.36. Further, the Quick Ratio stands at 4.36, while the Cash Ratio is 4.61. Considering the valuation of this stock, the price to sales ratio is 7.87, the price to book ratio is 4.00.
